SCHEMBL10133154

SCHEMBL10133154

CN1CCN(c2ccc(Oc3ccc(CNC(=O)Cc4ccccc4)nc3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.54
RAB9A P51151 2/20 0.54
POLB P06746 1/20 0.46
SRC P12931 2/20 0.46
ABL1 P00519 1/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
LYN P07948 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
BCR P11274 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
TUBA1A Q71U36 1/20 0.46
TUBA1C Q9BQE3 1/20 0.46
TUBB6 Q9BUF5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10133145 0.90 RAB9A (0.53) NPC1RAB9APOLBSRCABL1
SCHEMBL10133151 0.89 RAB9A (0.53) NPC1RAB9APOLBSRCABL1
SCHEMBL10133156 0.87 NPC1 (0.62) NPC1RAB9ACCR3KMT2AMAPT
SCHEMBL10133177 0.84 POLB (0.60) NPC1RAB9APOLBKMT2AMAPT
SCHEMBL10133139 0.80 TUBB4A (0.71) NPC1RAB9ASRCABL1TUBB4A
SCHEMBL10133148 0.80 RAB9A (0.58) NPC1RAB9ACCR3FLT3KMT2A
SCHEMBL10133152 0.80 RAB9A (0.58) NPC1RAB9ACCR3FLT3KMT2A
SCHEMBL10133034 0.77 TUBB4A (0.70) NPC1RAB9APOLBSRCABL1
SCHEMBL10133168 0.75 POLB (0.60) NPC1RAB9APOLBSRCABL1
SCHEMBL10133125 0.72 TUBB4A (0.70) SRCABL1TUBB4ATUBBLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
WO-2009009041-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE KINEX PHARMACEUTICALS, LLC (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 NPC1 3447/4885RAB9A 2804/4885POLB 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.